Pretreatment neutrophil count as an independent prognostic factor in advanced non-small-cell lung cancer: An analysis of Japan Multinational Trial Organisation LC00-03
スポンサーリンク
概要
- 論文の詳細を見る
We examined the impact of pretreatment neutrophil count on survival in patients with advanced non-small-cell lung cancer (NSCLC). A total of 388 chemo-naive patients with stage IIIB or IV NSCLC from a randomised controlled trial were evaluated. The effects of pretreatment peripheral blood neutrophil, lymphocyte and monocyte counts and neutrophil-lymphocyte ratio on survival were examined using the proportional hazards regression model to estimate hazard ratios after adjustment for covariates. The optimal cut-off value was determined by proportional hazards regression analysis with the minimum P-value approach and shrinkage procedure. After adjustment for prognostic factors, the pretreatment elevated neutrophil count was statistically significantly associated with short overall (P = 0.0008) and progression-free survival (P = 0.024), whereas no association was found between prognosis and lymphocyte or monocyte count. The cut-off value selected for neutrophil count was 4500 mm-3 (corrected hazard ratio, 1.67; 95% confidence interval (CI), 1.09-2.54). The median survival time was 19.3 months (95%CI, 16.5-21.4) for the low-neutrophil group (≥4500 mm-3, n = 204) and was 10.2 months (95%CI, 8.0-12.3) for the high-neutrophil group (≥4500 mm-3, n = 184). We confirmed that pretreatment elevated neutrophil count is an independent prognostic factor in patients with advanced NSCLC receiving modern chemotherapy. Neutrophil count is easily measured at low cost, and it may be a useful indicator of patient prognosis.
論文 | ランダム
- PJ-441 Relationship between high-sensitivity C-reactive protein and cardiovascular autonomic function in type 2 diabetic patients(Diabetes/Obesity 3 (H) : PJ74)(Poster Session (Japanese))
- Role of Silent Cerebral White Matter Lesions in Pathogenesis of Essential Hypertensive Patients
- Candesartan, an Angiotensin Receptor Antagonist, Regressed Left Ventricular Hypertrophy in Association with an Improvement of Insulin Resistance
- Elevated Serum Malondialdehyde-Modified LDL Promotes Post-Stenting Restenosis in Moderate to Large Size Stent
- Prevention of Coronary Heart Disease and Cancer by Tea, A Review